Production (Stage)
Amicus Therapeutics, Inc.
FOLD
$6.22
-$0.04-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -16.34% | 5.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.34% | 5.79% | |||
| Cost of Revenue | -21.15% | 11.73% | |||
| Gross Profit | -15.81% | 5.17% | |||
| SG&A Expenses | 5.95% | 15.39% | |||
| Depreciation & Amortization | -10.00% | -5.94% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.40% | 14.58% | |||
| Operating Income | -149.79% | -35.61% | |||
| Income Before Tax | -327.44% | 16.93% | |||
| Income Tax Expenses | 153.50% | -150.36% | |||
| Earnings from Continuing Operations | -247.13% | 319.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -247.13% | 319.04% | |||
| EBIT | -149.79% | -35.61% | |||
| EBITDA | -133.95% | -33.22% | |||
| EPS Basic | -246.57% | 317.65% | |||
| Normalized Basic EPS | -326.54% | -20.59% | |||
| EPS Diluted | -246.57% | 317.65% | |||
| Normalized Diluted EPS | -326.54% | -20.59% | |||
| Average Basic Shares Outstanding | 0.50% | 0.48% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||